Zoetis (NYSE:ZTS) had its price target lifted by BMO Capital Markets to $78.00 in a research note released on Tuesday morning, The Fly reports. They currently have a market perform rating on the stock.
A number of other equities analysts have also commented on ZTS. Citigroup upgraded Zoetis from a neutral rating to a buy rating and set a $85.00 price objective on the stock in a research note on Thursday, January 4th. BidaskClub lowered Zoetis from a strong-buy rating to a buy rating in a research note on Wednesday, September 20th. Cantor Fitzgerald set a $85.00 price objective on Zoetis and gave the stock a buy rating in a research note on Tuesday, January 2nd. Craig Hallum reiterated a buy rating and issued a $85.00 price objective (up from $77.00) on shares of Zoetis in a research note on Tuesday, January 2nd. Finally, Zacks Investment Research lowered Zoetis from a buy rating to a hold rating in a research note on Saturday, January 6th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. Zoetis has a consensus rating of Buy and a consensus target price of $71.28.
Shares of Zoetis (NYSE ZTS) traded up $0.68 during trading hours on Tuesday, hitting $74.59. The company’s stock had a trading volume of 1,629,200 shares, compared to its average volume of 2,425,500. Zoetis has a 12 month low of $52.00 and a 12 month high of $75.47. The firm has a market capitalization of $36,600.00, a PE ratio of 39.26, a P/E/G ratio of 1.91 and a beta of 1.06. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.68%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. Zoetis’s payout ratio is currently 22.11%.
A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Janus Henderson Group PLC increased its stake in Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after acquiring an additional 5,734,776 shares during the period. BlackRock Inc. increased its stake in Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares during the period. AJO LP increased its stake in Zoetis by 4,506.8% during the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after acquiring an additional 1,243,826 shares during the period. Thrivent Financial For Lutherans increased its stake in Zoetis by 642.7% during the second quarter. Thrivent Financial For Lutherans now owns 1,336,033 shares of the company’s stock valued at $83,342,000 after acquiring an additional 1,156,142 shares during the period. Finally, Vanguard Group Inc. increased its stake in Zoetis by 2.8% during the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares during the period. Hedge funds and other institutional investors own 93.19% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.com-unik.info/2018/01/12/bmo-capital-markets-boosts-zoetis-zts-price-target-to-78-00.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis and related companies.